EVERSANA Scales AI Commercialization Platform for Life Sciences
Pharmaceutical firms are moving past experimental pilot programs toward integrated, scalable technology, according to EVERSANA CEO Mark Thierer. The company announced on August 20 a major expansion of its AI-powered platform, adding new capabilities in medical affairs and market research to streamline commercial operations for life sciences organizations.
The updated platform, originally designed for agency marketing, now integrates agentic AI orchestration and workflow automation to support complex tasks like MLR automation, content development, and knowledge management. By linking these functions, the company aims to move clients away from isolated workflows and toward a unified ecosystem that maintains the strict governance and scientific rigor required in the pharmaceutical sector.
EVERSANA intends to continue this expansion with upcoming tools focused on patient services, sales enablement, and market access. The company plans to showcase these developments on August 27 in New York, where industry leaders will demonstrate how they are currently utilizing the platform to accelerate therapy delivery. This push reflects a broader industry shift toward AI-enabled operating models that augment human expertise while increasing overall operational efficiency.
Comments (0)
No comments yet. Be the first!